Fennec Pharmaceuticals Set to Release Quarterly Financial Results
RESEARCH TRIANGLE PARK, N.C. -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a dedicated specialty pharmaceutical company, has made an important announcement regarding its first quarter financial results for 2025. The company is on track to unveil these results before the U.S. financial markets open on a Tuesday in the mid-May timeframe of 2025.
On this significant day, management will also host a conference call and webcast to delve into Fennec's financial performance and business updates, offering stakeholders a comprehensive overview of what to expect moving forward.
Conference Call and Webcast Information
This conference call and accompanying webcast are essential for investors and interested parties wanting to keep abreast of Fennec’s developments. Below are the details regarding the timing and access:
When and Where
The conference call is set for the morning hours at 8:30 a.m. ET on the designated Tuesday in May. Interested participants are encouraged to connect through the company’s official website where the webcast will be available. It's advisable to log onto www.fennecpharma.com at least 15 minutes prior to the start to ensure a smooth experience.
Important Links
To access the live presentation, the company recommends visiting the News & Events/Event Calendar section under the Investors & Media section of their website. Additionally, those unable to attend the live call will have the opportunity to listen to the replay, which will be archived for thirty days post-event, enhancing accessibility for their audience.
About Fennec Pharmaceuticals and PEDMARK
Fennec Pharmaceuticals Inc. is making significant strides in the pharmaceutical industry, particularly with their product PEDMARK, aimed at mitigating the risk of platinum-induced ototoxicity experienced by pediatric patients undergoing chemotherapy. This innovative treatment has garnered approvals from the FDA and the European Commission, marking a pivotal moment for the company and its patients.
With FDA approval received in September 2022, and subsequent approvals from the European Commission and U.K. health authorities in mid-2023, PEDMARK has been rebranded as PEDMARQSI. The product has also been awarded Orphan Drug Exclusivity in the U.S., reflecting its critical importance and specialized nature in treatment.
In addition to providing essential therapy for young patients, PEDMARQSI has achieved Pediatric Use Marketing Authorization in Europe, ensuring it enjoys an extensive data and market protection period, encompassing eight years plus an additional two years.
Investor Relations Contacts
For those seeking further insights or clarifications, Fennec Pharmaceuticals encourages reaching out to their dedicated contacts. Investors can contact Robert Andrade, the Chief Financial Officer, via phone at +1 919-246-5299 for any financial inquiries.
Furthermore, corporate and media queries can be directed to Lindsay Rocco at Elixir Health Public Relations at +1 862-596-1304 or via email at lrocco@elixirhealthpr.com.
Frequently Asked Questions
What date will Fennec Pharmaceuticals release its Q1 2025 results?
The company plans to release its first quarter 2025 financial results on a Tuesday in mid-May 2025.
How can I access the Fennec Pharmaceuticals conference call?
Participants can access the conference call by visiting www.fennecpharma.com and navigating to the relevant news section.
What is PEDMARK?
PEDMARK is a treatment developed by Fennec Pharmaceuticals designed to reduce the risk of ototoxicity in children receiving platinum-based chemotherapy.
What approvals has PEDMARK received?
PEDMARK has received approvals from the FDA and the European Commission, along with additional approvals in the U.K., solidifying its important role in pediatric care.
Whom should I contact for more information about Fennec Pharmaceuticals?
For inquiries, investors should reach out to Robert Andrade, while media inquiries can be directed to Lindsay Rocco at Elixir Health Public Relations.
